IgAN late-breakers led the meeting, alongside new data on aspirin, dialysis access, donor pregnancy, potassium, and depression.
News|Articles|November 3, 2026
8 Nephrology Headlines You Missed in October 2026
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.
Advertisement
Advertisement
Related to this article
In 1200 patients with solid tumors, creatinine-based eGFR identified CKD in 10.2% vs 18.9% by measured GFR, often missing chemotherapy dosing cutoffs.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.
Experts discuss remibrutinib, the first FDA-approved therapy for symptomatic dermographism: RemIND data, bleeding counseling, and where it fits in practice
The FDA has pushed its decision on mitapivat for sickle cell disease to February 1, 2027, while it reviews updated safety data to decide whether a REMS is needed.
Stephen Seliger, MD, and Michel Chonchol, MD, join Kidney Compass to discuss a pilot trial of empagliflozin in rapidly progressing ADPKD.
Advertisement
Advertisement